I have been active in clinical research since I joined IUSM in 1995 and my work has been published in Nature Medicine and New England Journal of Medicine among others. My Role as a leader of the Multiple Myeloma program has allowed me to participate in practice changing research using IMID's and Proteasome inhibitors. I have facilitated clinical research at IU Simon Cancer Center and IU School as the Medical director of clinical research and the associated dean for clinical research. I have focused on Myeloma and with the help of the IU Grand Challenge Grant we are putting together the infrastructure to support highly competitive team of researchers and conduct research aimed at preventing myeloma and improving the treatment of those suffering from the disease especially those with high risk disease where both remission and survival is short. I am also active with the international Myeloma Foundation and the American Society of Hematology (ASH). My outside collaboration has focused on disease registry to help understand the course of disease outside clinical trials. I Chair the steering committee of one (Connect MM) and member of the steering committee of another (Insight). My collaboration with ASH is focused on database harmonization to develop larger set of patients data to help understand the natural course of myeloma.
Die Entwicklung der Krankheit durchläuft mehrere Stadien, zwischen denen es keine klare Unterteilung gibt - alles hängt von den individuellen Merkmalen https://masculputernic.com/de/ der Wahrnehmung, des Immunsystems und der Aktivität des Entzündungsprozesses ab.
Residency - University of Wisconsin, Madison; Sinai Samaritan Medical Center, Milwaukee, WI
M.D. - University of Damascus, Damascus, Syria
Fellowship - University of Wisconsin, Madison, WI
Internship - Sinai Samaritan Medical Center, Milwaukee, WI
